Skip to main content
Lonza Group AG logo

Lonza Group AG — Investor Relations & Filings

Ticker · LONN ISIN · CH1255014495 LEI · 549300EFW4H2TCZ71055 SW Manufacturing
Open in API
Filings indexed 137 across all filing types
Latest filing 2021-06-02 M&A Activity
Country CH Switzerland
Listing SW LONN

About Lonza Group AG

https://www.lonza.com/

Lonza Group AG is a global contract development and manufacturing organization (CDMO) that partners with the pharmaceutical, biotech, and nutrition industries. The company provides integrated services that span the entire product lifecycle, from early-phase research and process development to custom, large-scale commercial manufacturing. Its expertise covers a wide range of therapeutic modalities, including mammalian and microbial biopharmaceuticals, small molecules, cell and gene therapies, highly potent active pharmaceutical ingredients (APIs), peptides, and bioconjugates. By combining advanced scientific and technological insights with world-class manufacturing and regulatory expertise, Lonza supports its customers in developing and commercializing innovative medicines and health products for patients worldwide.

Recent filings

Filing Released Lang Actions
Lonza and Moderna Announce Further Collaboration For Drug Substance Manufacturing of COVID-19 Vaccine Moderna in the Netherlands
M&A Activity Classification · 99% confidence The document is titled 'News Details' and is explicitly labeled as an 'Ad-hoc' announcement released on '2 June 2021'. It states, 'Release of an ad hoc announcement pursuant to Art. 53 KR'. This type of announcement, detailing a significant business event (expansion of collaboration for drug substance manufacturing) that is not a standard periodic financial report (like 10-K or IR) or a specific corporate action (like DIV or SHA), falls best under the general category for regulatory announcements that don't fit elsewhere. Since it is a formal, time-sensitive disclosure required by regulation (Art. 53 KR suggests a regulatory requirement), and it doesn't match the specific definitions for ER, CT, MANG, DIRS, etc., the most appropriate classification is the general regulatory filing fallback category.
2021-06-02 English
Lonza Announces Expansion Plans for Next-Generation Mammalian Manufacturing Facilities in Visp (CH) and Portsmouth (US)
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as an "Ad-hoc" announcement released on May 6, 2021, and states it is a "Release of an ad hoc announcement pursuant to Art. 53 KR". The content details significant investment plans (CHF 850 million) for expanding manufacturing facilities, which constitutes a major corporate event impacting the company's operations and future capacity. This type of material announcement, which is not a standard periodic financial report (like 10-K or IR) or a specific shareholder vote result, typically falls under general regulatory announcements or capital/financing updates. Since it details a major capital expenditure and expansion strategy, it strongly relates to 'Capital/Financing Update' (CAP). However, given the context of being an immediate, non-scheduled disclosure of material information (Ad-hoc), and lacking specific keywords for the other categories (like Director's Dealing, Dividend, or M&A), the most appropriate general classification for a significant, immediate corporate action announcement that isn't a standard report is often the general regulatory filing category, or if the focus is purely on the capital deployment, CAP. Since the core message is about a major investment (capital deployment) and expansion, CAP is a strong candidate. If it were purely a press release without the regulatory context, it might be RNS. Given the nature of the announcement (major investment/expansion), I will classify it as a Capital/Financing Update (CAP), as it directly concerns capital structure changes and fundraising/investment decisions, even if not a formal offering document. If CAP is too specific, RNS is the fallback. Given the focus on CHF 850 million investment, CAP is the best fit among the specific options.
2021-05-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.